Financial PositionGOSS ended the year with $294.5M in cash, expected to fund operations into the first half of 2027, indicating a stable financial position.
Study EnrollmentThe final enrollment number of 390 in the Phase 3 PROSERA study is higher than expected, indicating strong interest and participation.
Therapeutic PotentialSeralutinib's differentiated mechanism of action, targeting vascular remodeling, positions it as a potential best-in-class therapy for pulmonary arterial hypertension.